CA2544245A1 - Use of selective opiate receptor modulators in the treatment of neuropathy - Google Patents

Use of selective opiate receptor modulators in the treatment of neuropathy Download PDF

Info

Publication number
CA2544245A1
CA2544245A1 CA002544245A CA2544245A CA2544245A1 CA 2544245 A1 CA2544245 A1 CA 2544245A1 CA 002544245 A CA002544245 A CA 002544245A CA 2544245 A CA2544245 A CA 2544245A CA 2544245 A1 CA2544245 A1 CA 2544245A1
Authority
CA
Canada
Prior art keywords
compounds
neuropathy
opiate receptor
treatment
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002544245A
Other languages
English (en)
French (fr)
Inventor
Gerd Bartoszyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tioga Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2544245A1 publication Critical patent/CA2544245A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002544245A 2003-10-30 2004-10-14 Use of selective opiate receptor modulators in the treatment of neuropathy Abandoned CA2544245A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03024781.1 2003-10-30
EP03024781 2003-10-30
PCT/EP2004/011548 WO2005046687A1 (en) 2003-10-30 2004-10-14 Use of selective opiate receptor modulators in the treatment of neuropathy

Publications (1)

Publication Number Publication Date
CA2544245A1 true CA2544245A1 (en) 2005-05-26

Family

ID=34585870

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002544245A Abandoned CA2544245A1 (en) 2003-10-30 2004-10-14 Use of selective opiate receptor modulators in the treatment of neuropathy

Country Status (7)

Country Link
US (1) US20080090859A1 (enExample)
EP (1) EP1680115A1 (enExample)
JP (2) JP2007509865A (enExample)
AR (1) AR046219A1 (enExample)
AU (1) AU2004288641B2 (enExample)
CA (1) CA2544245A1 (enExample)
WO (1) WO2005046687A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CA2682608A1 (en) 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
CN114678927A (zh) * 2022-03-22 2022-06-28 浙江地芯引力科技有限公司 一种充电线材充电控制方法、充电线材

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2550077A (en) * 1976-06-14 1978-11-30 Merck Patent Gmbh Penicillins and cephalosporins
DE3738844A1 (de) * 1987-11-16 1989-05-24 Merck Patent Gmbh Analgetikum
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4407047A1 (de) * 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
RU2275915C2 (ru) * 1999-11-03 2006-05-10 Бристол-Маерс Сквибб Компани Способ лечения диабета
US6525062B2 (en) * 2000-06-09 2003-02-25 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
AU2003209851A1 (en) * 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
PL371596A1 (en) * 2002-05-17 2005-06-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren

Also Published As

Publication number Publication date
WO2005046687A1 (en) 2005-05-26
AU2004288641A1 (en) 2005-05-26
EP1680115A1 (en) 2006-07-19
JP2013035873A (ja) 2013-02-21
AU2004288641B2 (en) 2010-08-12
JP2007509865A (ja) 2007-04-19
US20080090859A1 (en) 2008-04-17
AR046219A1 (es) 2005-11-30

Similar Documents

Publication Publication Date Title
US10857204B2 (en) Method for administering omega-conopeptide
JP4925074B2 (ja) ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
US11529337B2 (en) Method of treating pain
RU2135179C1 (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
CN105367485B (zh) 用于预防和/或治疗中枢神经系统退行性失调的新颖组合物
SK286621B6 (sk) Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva
US20120077818A1 (en) Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
PL200490B1 (pl) Nowe zastosowanie 1-[4-(5-cyjanoindol-3-ilo)butylo]-4-(2-karbamoilobenzofuran-5-ylo)piperazyny oraz jej fizjologicznie tolerowanych soli
US6521266B1 (en) Composition for growth hormone production and release, appetite suppression, and methods related thereto
US20120010125A1 (en) Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
US5340826A (en) Pharmaceutical agents for treatment of urinary incontinence
AU2004288641B2 (en) Use of selective opiate receptor modulators in the treatment of neuropathy
KR100195651B1 (ko) 신경 손상 및 발작의 치료를 위한 nk-1 수용체 길항물질
TWI457123B (zh) ４－｛３－［順式－六氫環戊并［ｃ］吡咯－２（１ｈ）－基］丙氧基｝苯甲醯胺與ｎｍｄａ受體拮抗劑之新結合及包含彼等之醫藥組合物
SK2582004A3 (en) Use of desoxypeganine for treating clinical depression
PT95698B (pt) Processo para a preparacao de composicoes farmaceuticas contendo aril-alquilamidas utilizadas no tratamento de doencas neurodegenarativas
WO2012054817A1 (en) Delaying and/ or treating hyperglycemia, including diabetes, with poly(alkyl carboxylic acids)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141106